


Together, we are advancing the prevention, detection, and treatment of Alzheimer's disease.

AD-RIDDLE aims to address challenges in the management of Alzheimer's disease, speeding up patient access to healthcare providers and precision medicine.

As the global population ages, the number of people with dementia is forecasted to grow from over 57 million today to 153 million by 2050. While there's great potential for risk reduction and early interventions to improve patient outcomes, broadly available testing, diagnosis, and treatment options are essential to prepare our healthcare systems for the influx of patients.

AD-RIDDLE centres around a modular toolbox platform that will match patients with the right interventions at the right time, at every stage of the clinical pathway.



AD-RIDDLE's modular toolbox platform will allow healthcare systems and providers to mix, match, and tailor its components to best suit their unique needs and settings. It will provide support at all stages of the clinical pathway to speed up patient access to healthcare providers and precision medicine.

Digital Community Engagement Platform

AD-RIDDLE's digital platform will include self-guided assessment tools and pathways for timely referral to healthcare providers, and tailored resources that connect to the next best step.

Accessible & Validated Screening Tools

Providers will have access to a suite of validated digital cognitive assessments and blood-based biomarkers, intended to increase accuracy in risk detection and early diagnosis.

Decision Support Toolkit

The toolkit for healthcare providers will unite best-in-class research, science, and outcomes data to enable differential diagnosis and inform personalised plans for prevention and care.

Personalised Patient Therapies

Patients will be matched with the right interventions at the right time, including lifestyle interventions and pharmacological treatments.

We're collaborating to advance Alzheimer's research and care.

The AD-RIDDLE consortium unites 24 public and private leaders from across Europe to revolutionise the prevention and treatment of Alzheimer's disease.



The AD-RIDDLE toolbox platform builds on existing technology, tools, and biomarkers, many developed by AD-RIDDLE Consortium partners through earlier EU-funded projects, including WW-FINGERS.



A three-year real-world testing study will be conducted in healthcare settings across 6 European countries. Data from the AD-RIDDLE study will be hosted in a GDPR-compliant manner by EPND.

Stay up to date on the development of the AD-RIDDLE platform:

Visit ad-riddle.org or contact info@ad-riddle.org for updates as our work progresses.